期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 30, 期 -, 页码 113-117出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2016.03.010
关键词
HES1; NOTCH; Cancer; Immunity; Cytokine; Therapy
资金
- Medical Research Council [MR/J006742/1] Funding Source: Medline
- Medical Research Council [MR/J006742/1] Funding Source: researchfish
Hairy and enhancer of split homolog-1 (HES1) is a part of an extensive family of basic helix -loop -helix (bHLH) proteins and plays a crucial role in the control and regulation of cell cycle, proliferation, cell differentiation, survival and apoptosis in neuronal, endocrine, T-lymphocyte progenitors as well as various cancers. HES1 is a transcription factor which is regulated by the NOTCH, Hedgehog and Wnt signalling pathways. Aberrant expression of these pathways is a common feature of cancerous cells. There appears to be a fine and complicated crosstalk at the molecular level between the various signalling pathways and HES1, which contributes to its effects on the immune response and cancers such as leukaemia. Several mechanisms have been proposed, including an enhanced invasiveness and metastasis by inducing epithelial mesenchymal transition (EMT), in addition to its strict requirement for tumour cell survival. In this review, we summarize the current biology and molecular mechanisms as well as its use as a clinical target in cancer therapeutics. (C) 2016 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据